Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias. Based on our survey results, the U.S. reimbursement environment already restricts the prescription of high-priced MDS medications, and treatment costs are set to increase with the expected approval of new agents, including BristolMyers Squibb / Acceleron’s Reblozyl. In this report, we analyze in depth the current and anticipated uptake of MDS therapies. In addition, we examine how MCO formulary decisions and utilization controls on both the pharmacy benefit and medical benefit affect the prescribing of surveyed hematologists.
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.
Release date: June 2020
Geography: United States
Primary research: Survey of 100 U.S. hematologists and 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs / MDs).
Fingertip formulary: Formulary coverage and restrictions data for MDS therapies by commercial plans covering approximately 166 million lives and Medicare Part D plans covering 35 million lives nationally.
Key drugs covered: Vidaza, Revlimid, Dacogen, Epogen, Aranesp, Procrit
Key analysis provided: